期刊
BIOCONJUGATE CHEMISTRY
卷 19, 期 1, 页码 39-49出版社
AMER CHEMICAL SOC
DOI: 10.1021/bc070031k
关键词
-
类别
资金
- NATIONAL CANCER INSTITUTE [R37CA034992, R01CA034992] Funding Source: NIH RePORTER
- NCI NIH HHS [R37 CA034992-17, CA34992, R37 CA034992, R01 CA034992] Funding Source: Medline
The integrins alpha(v)beta(3) and alpha(v)beta(5) and the membrane-spanning surface protein aminopeptidase N (APN) are highly expressed in tumor-induced angiogenesis, making them attractive targets for therapeutic intervention. Both integrins and APN recognize a broad range of peptides containing RGD (Arg-Gly-Asp) and NGR (Asn-Gly-Arg) motifs, respectively., Here, we describe the design, synthesis, and characterization of a series of mono- and difunctionalized platinum(IV) complexes in which a conjugated peptide motif, containing RGD, (CRGDC)c, (RGDfK)c, or NGR, is appended as a tumor-homing device to target tumor endothelial cells selectively over healthy cells. Platinum(IV)-peptide complexes with nonspecific amino acids or peptide moieties were prepared as controls. Concentration-response curves of these compounds were evaluated against primary proliferating endothelial cells and tumor cell lines and compared to those of cisplatin, a well-described platinum-based chemotherapeutic agent. The Pt(IV)-RGD conjugates were highly and specifically cytotoxic to cell lines containing alpha(v)beta(3) and alpha(v)beta(5), approaching the activity of cisplatin. The Pt(IV)-NGR complexes were less active than Pt(IV)-RGD-containing compounds but more active than nonspecific Pt-peptide controls. Integrin alpha(v)beta(3) mediated, at least in part, the anti-proliferative effect of a Pt(IV)-RGD conjugate, as demonstrated by a decreased inhibitory response when endothelial cells were either (1) incubated with an excess of alpha(v)beta(3)/alpha(v)beta(5)-specific RGD pentapeptides or (2) transfected with RNAi for beta(3), but not beta(1), integrins. These results suggest a rational approach to improved chemotherapy with Pt(IV)-peptide conjugates by selective drug delivery to the tumor compartment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据